Seven Eight Capital LP Acquires Shares of 18,971 Lantheus Holdings, Inc. (NASDAQ:LNTH)

Seven Eight Capital LP bought a new position in Lantheus Holdings, Inc. (NASDAQ:LNTH) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 18,971 shares of the medical equipment provider’s stock, valued at approximately $1,523,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Silverberg Bernstein Capital Management LLC increased its stake in shares of Lantheus by 0.4% during the 2nd quarter. Silverberg Bernstein Capital Management LLC now owns 22,843 shares of the medical equipment provider’s stock worth $1,834,000 after purchasing an additional 100 shares during the last quarter. Moody National Bank Trust Division grew its holdings in Lantheus by 1.1% during the second quarter. Moody National Bank Trust Division now owns 14,984 shares of the medical equipment provider’s stock valued at $1,203,000 after purchasing an additional 162 shares during the period. Shaker Investments LLC OH increased its position in Lantheus by 0.7% in the first quarter. Shaker Investments LLC OH now owns 27,962 shares of the medical equipment provider’s stock worth $1,740,000 after buying an additional 182 shares during the last quarter. NBC Securities Inc. raised its stake in shares of Lantheus by 28.4% in the first quarter. NBC Securities Inc. now owns 863 shares of the medical equipment provider’s stock valued at $53,000 after buying an additional 191 shares during the period. Finally, GAMMA Investing LLC lifted its position in shares of Lantheus by 184.1% during the 2nd quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider’s stock valued at $26,000 after buying an additional 208 shares during the last quarter. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Insider Activity

In related news, Director Gerard Ber sold 15,500 shares of the company’s stock in a transaction on Monday, August 12th. The shares were sold at an average price of $96.48, for a total value of $1,495,440.00. Following the completion of the transaction, the director now directly owns 21,221 shares in the company, valued at $2,047,402.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Lantheus news, Director Gerard Ber sold 15,500 shares of the company’s stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $96.48, for a total value of $1,495,440.00. Following the completion of the sale, the director now owns 21,221 shares of the company’s stock, valued at $2,047,402.08. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CAO Andrea Sabens sold 341 shares of Lantheus stock in a transaction that occurred on Monday, July 15th. The stock was sold at an average price of $123.15, for a total transaction of $41,994.15. Following the transaction, the chief accounting officer now directly owns 62,216 shares in the company, valued at $7,661,900.40. The disclosure for this sale can be found here. In the last quarter, insiders have sold 40,852 shares of company stock worth $3,922,001. 1.50% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several brokerages recently weighed in on LNTH. Redburn Atlantic began coverage on Lantheus in a report on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 price objective for the company. JMP Securities lowered their price target on shares of Lantheus from $130.00 to $125.00 and set a “market outperform” rating on the stock in a research report on Thursday, August 1st. B. Riley raised their price objective on shares of Lantheus from $105.00 to $146.00 and gave the stock a “buy” rating in a report on Thursday, July 25th. Truist Financial lowered their target price on shares of Lantheus from $141.00 to $135.00 and set a “buy” rating on the stock in a report on Thursday, August 1st. Finally, Leerink Partners raised their price target on Lantheus from $106.00 to $127.00 and gave the stock an “outperform” rating in a report on Thursday, July 11th. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $126.00.

Lantheus Price Performance

Lantheus stock opened at $108.56 on Friday. The stock has a market cap of $7.52 billion, a price-to-earnings ratio of 16.57 and a beta of 0.50. The company has a quick ratio of 4.41, a current ratio of 4.68 and a debt-to-equity ratio of 0.55. The business has a 50-day simple moving average of $105.78 and a 200 day simple moving average of $83.79. Lantheus Holdings, Inc. has a 52 week low of $50.20 and a 52 week high of $126.89.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings data on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share for the quarter, missing the consensus estimate of $1.68 by ($0.07). Lantheus had a return on equity of 48.36% and a net margin of 29.80%. The company had revenue of $394.10 million during the quarter, compared to the consensus estimate of $382.12 million. During the same quarter last year, the company posted $1.40 earnings per share. The firm’s revenue for the quarter was up 22.5% on a year-over-year basis. On average, research analysts forecast that Lantheus Holdings, Inc. will post 5.99 earnings per share for the current fiscal year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.